Evidence map›Paper›PMID 32235748›Full record

ArticleGels (Basel, Switzerland)2020

Elucidating the Structure-Function Relationship of Solvent and Cross-Linker on Affinity-Based Release from Cyclodextrin Hydrogels.

Sean T Zuckerman, Edgardo Rivera-Delgado, Rebecca M Haley, Julius N Korley, Horst A von Recum

Open access · goldAbstract read
In one paragraph

Article in Gels (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Sean T ZuckermanAffinity Therapeutics, LLC, 11000 Cedar Avenue, Suite 285, Cleveland, OH 44106, USA.ORCID 0000-0002-8074-8793
Edgardo Rivera-DelgadoDepartment of Biomedical Engineering, Case Western Reserve University, 10900 Euclid Avenue Cleveland, OH 44106, USA.
Rebecca M HaleyDepartment of Biomedical Engineering, Case Western Reserve University, 10900 Euclid Avenue Cleveland, OH 44106, USA.ORCID 0000-0001-7322-7829
Julius N KorleyAffinity Therapeutics, LLC, 11000 Cedar Avenue, Suite 285, Cleveland, OH 44106, USA.
Horst A von RecumDepartment of Biomedical Engineering, Case Western Reserve University, 10900 Euclid Avenue Cleveland, OH 44106, USA.ORCID 0000-0002-9323-8100
Case Western Reserve University · US

Funding

Cyclodextrin-based Microparticle Polymer Formulations for the Slow and SustainedR43GM100525 · NIGMS · AFFINITY THERAPEUTICS, LLC · PI KORLEY, JULIUS N. · 2012 to 2013
$400k
NIH HHS R43 GM100525
6 · The paper itself

Abstract

Minocycline (MNC) is a tetracycline antibiotic capable of associating with cyclodextrin (CD), and it is a frontline drug for many instances of implant infection. Due to its broad-spectrum activity and long half-life, MNC represents an ideal drug for localized delivery; however, classic polymer formulations, particularly hydrogels, result in biphasic release less suitable for sustained anti-microbial action. A polymer delivery system capable of sustained, steady drug delivery rates poses an attractive target to maximize the antimicrobial activity of MNC. Here, we formed insoluble hydrogels of polymerized CD (pCD) with a range of crosslinking densities, and then assessed loading, release, and antimicrobial activity of MNC. MNC loads between 5-12 wt % and releases from pCD hydrogels for >14 days. pCD loaded with MNC shows extended antimicrobial activity against

Indexed as

affinity-basedcyclodextrindrug deliveryminocyclinepolymerstructure-function relationship

Identifiers

PMID32235748
PMCPMC7151216
OpenAlexW3012627952

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.